Clinical trial
Vaccine Responses in Patients With B Cell Malignancies
NCT05170399 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Vaccine Responses in Patients With B Cell Malignancies
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- September 14, 2022
- Completion date
- November 15, 2036
- Enrollment
- 350 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.